Abstract: A counterweight slack detection switch including a body, a first belt guide mounted to the body and configured to engage a first side of a tension member, a second belt guide mounted to the body and configured to engage the first side of the tension member, a lever arm having a first end and a second end, the first end pivotally mounted to the body, a deflectable member biasing the lever arm relative to the body, a third belt guide mounted to the second end of the lever arm and configured to bias the tension member from a tension position to a slack position, and a switch mounted to the body and configured to contact the tension member when the tension member is in at least one of the tension position and the slack position.

Abstract: An adjustable hospital gown is designed to cover the bodies of users of varying shape and size. The gown has a torso-covering garment, a pair of backflaps, and an adjustable fastener. The torso-covering garment is used to cover the front side of the user's body. The pair of backflaps are connected along backflap seams that are positioned on opposite sides of the torso-covering garment. As a result, the pair of backflaps can be transitioned between an opened and a closed configuration. The adjustable fastener is connected in between one of the backflaps and the torso-covering garment such that the backflap can be repositioned to cinch the gown around the body of the user. By connecting the adjustable fastener to various anchor points, the size of the gown can be modified to accommodate user's of varying shape.

Abstract: The invention provides pharmaceutical compositions and method of using the compositions, wherein the compositions comprise liposomes or micelles that contain one or more targeting peptides and/or anticancer drugs. In various embodiments, the components of the liposomes can include a) a phospholipid and optionally a lipid that is not a phospholipid; b) a pegylated lipid; c) a peptide-ethylene glycol (EG)-lipid conjugate wherein the peptide is a targeting ligand, and d) one or more drug-conjugated lipid, encapsulated drugs, or a combination thereof. The peptide-EG-lipid conjugate can be, for example, a compound of Formula (I) or Formula (II). The ethylene glycol (EG) segments of the peptide-EG-lipid conjugate can be, for example, EG6 to about EG36; and the EG segment can be conjugated to one or more lysine moieties.

Abstract: An imaging apparatus including a user interface generating displays for optimizing a user's experience when indicating preferred options prior to performing a function. Displays for relatively large user interfaces are bifurcated into a settings pane including a plurality of settings associated with the selected function and a preset pane including a preconfigured set of settings and options for the same function. A transparent drawer—including specific settings and/or options corresponding to a setting from the settings pane—is operative to be launched and closed when the said setting has been selected and deselected, respectively. Selected options are implicitly stored and automatically summarized on the settings pane. Displays for relatively small user interfaces also feature a bifurcated display manifested by a resizable settings pane operative to expand and reduce in response to user input, the resizable settings pane featuring a summary of selected options.

Abstract: An imaging apparatus including a user interface generating displays for optimizing a user's experience when indicating preferred options prior to performing a function. Displays for relatively large user interfaces are bifurcated into a settings pane including a plurality of settings associated with the selected function and a preset pane including a preconfigured set of settings and options for the same function. A transparent drawer—including specific settings and/or options corresponding to a setting from the settings pane—is operative to be launched and closed when the said setting has been selected and deselected, respectively. Selected options are implicitly stored and automatically summarized on the settings pane. Displays for relatively small user interfaces also feature a bifurcated display manifested by a resizable settings pane operative to expand and reduce in response to user input, the resizable settings pane featuring a summary of selected options.

Abstract: The invention provides pharmaceutical compositions and method of using the compositions, wherein the compositions comprise liposomes or micelles that contain one or more targeting peptides and/or anticancer drugs. In various embodiments, the components of the liposomes can include a) a phospholipid and optionally a lipid that is not a phospholipid; b) a pegylated lipid; c) a peptide-ethylene glycol (EG)-lipid conjugate wherein the peptide is a targeting ligand, and d) one or more drug-conjugated lipid, encapsulated drugs, or a combination thereof. The peptide-EG-lipid conjugate can be, for example, a compound of Formula (I) or Formula (II). The ethylene glycol (EG) segments of the peptide-EG-lipid conjugate can be, for example, EG6 to about EG36; and the EG segment can be conjugated to one or more lysine moieties.

Abstract: Waste streams from different chloromonosilane production processes are combined and reacted in a single recovery process. Useful monosilane species may be obtained with a single recovery process.

Abstract: A NOx storage component comprises caesium silicate (Cs2SiO3) and at least one platinum group metal. The invention also includes a NOx absorber catalyst comprising a NOx storage component according to the invention disposed on a substrate monolith; a method of treating exhaust gas containing NOx from a lean burn internal combustion engine comprising the steps of contacting a NOx storage component comprising caesium silicate (Cs2SiO3) and at least one platinum group metal with lean exhaust gas containing NOx to adsorb NOx thereon; and periodically desorbing adsorbed NOx by contacting the NOx storage component with stoichiometric or rich exhaust gas; and a method of making a NOx storage component according to the invention comprising the steps of combining and reacting an aqueous salt of at least one platinum group metal, an aqueous caesium salt and a source of silica.

Abstract: A NOx storage component comprises caesium silicate (Cs2SiO3) and at least one platinum group metal. The invention also includes a NOx absorber catalyst comprising a NOx storage component according to the invention disposed on a substrate monolith; a method of treating exhaust gas containing NOx from a lean burn internal combustion engine comprising the steps of contacting a NOx storage component comprising caesium silicate (Cs2SiO3) and at least one platinum group metal with lean exhaust gas containing NOx to adsorb NOx thereon; and periodically desorbing adsorbed NOx by contacting the NOx storage component vent with stoichiometric or rich exhaust gas; and a method of making a NOx storage component according to the invention comprising the steps of combining and reacting an aqueous salt of at least one platinum group metal, an aqueous caesium salt and a source of silica.

Abstract: A side recovery system is disclosed that includes a base configured to be supported on a vehicle and a boom supported by the base and having a first end and a second end. The boom is rotatable relative to the base about a substantially horizontal axis between a first position and second position. The second end of the boom being positioned at a first side of the vehicle in the first position and at an opposite second side of the vehicle in the second position. The system also includes a first sheave supported at the second end of the boom and configured to receive a load bearing cable. The cable configured to remain received by the first sheave as the boom rotates between the first position and the second position.